Australian company has approval already with FDA, EMA and TGA for bone application of its collagen scaffold product. Announced results in nerve application recently and.met FDA 510K study requirement. About to announce results from joint trial in tendon stem-cells (Tenocytes) with DePuy Synthes of J&J.
https://www.google.com/amp/s/www.proactiveinvestors.com.au/companies/amp/news/958895
Per the article growing revenues, but still a young company that like many bio-techs suffered during COVID lockdown. Trades at less than $100 million mkt cap (AUD) despite tendon and nerve markets being at least $10 billion markets respectively.
Starting to generate revenues but probably needs a J&J partnership like Fate Therapeutics had last year to take off.
Submitted August 30, 2021 at 09:03AM by Historical_Job_8609 https://ift.tt/3zv7Wio
